LSIPR 50 2018: The entrepreneurial bug
18-07-2018
Flamingo Images / Shutterstock.com
Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.
The strength of a company’s IP is a central factor in determining its value, and perhaps nowhere is this more evident than in the life sciences industry. Because of the huge upfront expenditures required to develop products in the pharmaceutical, biotechnology, and other life sciences industries, a strong IP portfolio can be the difference between success and failure.
Life sciences entrepreneurs often face different IP challenges from those in other industries due to long product life cycles and expensive research and development (R&D), among other concerns.
Long product life cycles
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Fish & Richardson, entrepreneurs, IP portfolio, pharmaceuticals, biotechnology, life sciences, R&D, patent protection, investment, FDA, infringement
